Get the Stockscreener App
4.98
4.78%
-0.25
Bioxcel Therapeutics Inc stock is traded at $4.98, with a volume of 3.90M.
It is down -4.78% in the last 24 hours and up +175.90% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$5.23
Open:
$5.24
24h Volume:
3.90M
Relative Volume:
0.51
Market Cap:
$72.49M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.8111
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
-9.12%
1M Performance:
+175.90%
6M Performance:
+133.80%
1Y Performance:
+663.69%
1-Day Range:
$4.90
$5.60
1-Week Range:
$4.46
$6.85
52-Week Range:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
4.98 | 82.54M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
Price Floor Holding on BioXcel Therapeutics Inc. — Rebound Possible2025 Volatility Report & Fast Gain Swing Alerts - beatles.ru
Chartists See Breakout Potential in BioXcel Therapeutics Inc.July 2025 Spike Watch & Long-Term Growth Portfolio Plans - thegnnews.com
Bioxcel Therapeutics Files Prospectus for $80M Share Sale - MSN
BioXcel Jumps On Speculation Of A Big Biotech Breakthrough - Finimize
BioXcel Therapeutics announces pre-sNDA meeting responses from FDA - MSN
Bioxcel Therapeutics (BTAI.O) Sees Sharp Intraday Drop—What’s Really Behind It? - AInvest
BioXcel Therapeutics completes database lock for SERENITY Phase 3 trial - TipRanks
BioXcel completes database lock for SERENITY At-Home trial - Investing.com
BioXcel Therapeutics announces database lock in Serenity at-home pivotal phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia - MarketScreener
BioXcel Therapeutics Completes SERENITY At-Home Pivotal Phase 3 Trial Database Lock - AInvest
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - The Manila Times
BioXcel Therapeutics Announces Database Lock in SERENITY - GlobeNewswire
Bioxcel Therapeutics: HC Wainwright Reiterates Buy, Raises PT to $10 - AInvest
2,600+ Patient Episodes: BioXcel's Groundbreaking Phase 3 Trial for First At-Home Agitation Treatment - Stock Titan
BioXcel Therapeutics Receives Positive FDA Feedback - MSN
BioXcel Therapeutics’ BXCL501 Gains Momentum with FDA Support and Positive Phase 3 Trial Outcomes, Analyst Recommends Buy with $10 Price Target - TipRanks
Bioxcel Therapeutics shares fall 9.35% premarket despite positive FDA pre-sNDA meeting comments. - AInvest
Bioxcel Therapeutics Plunges 11.82% on Share Sale Plan - AInvest
Bioxcel Therapeutics shares fall 13.58% premarket despite positive FDA pre-sNDA meeting comments. - AInvest
Can BioXcel Therapeutics Inc. Outperform Peers After Recent Pullback2025 Geopolitical Influence & Smart Allocation Stock Tips - 선데이타임즈
BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label - Stocktwits
BioXcel's $220M Volume Spike Propels 3.47% Rally Ranks 416th in Market Activity as FDA Aligns on Home-Use Label Expansion - AInvest
BioXcel Therapeutics files prospectus supplement for $80 million ATM program - Investing.com Nigeria
Bioxcel Therapeutics shares rise 2.12% after-hours following positive FDA pre-sNDA meeting comments. - AInvest
BioXcel receives FDA alignment for IGALMI at-home use submission By Investing.com - Investing.com Nigeria
BTAI Stock Soars: Time to Buy? - timothysykes.com
Bioxcel Therapeutics Surges 10.76%: Unraveling the Intraday Move - AInvest
BioXcel Therapeutics: Poised for a Major Breakthrough? - StocksToTrade
BioXcel Therapeutics’ Stock Soars Amid Promising Clinical Trials and Raised Price Target - timothysykes.com
BioXcel Therapeutics stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com Australia
BioXcel Therapeutics Stock Surges on FDA Positive Meeting Comments - AInvest
BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On? - inkl
BioXcel Therapeutics Announces Positive FDA Pre-SNDA Meeting Comments For SNDA Submission For Bxcl501 In Agitation Associated With Bipolar Disorders Or Schizophrenia - TradingView
Growth or Bubble? Examining BioXcel’s Surge - StocksToTrade
BioXcel Therapeutics announces positive FDA pre-sNDA meeting comments for sNDA submission for BXCL501 in agitation associated with bipolar disorders or schizophrenia - MarketScreener
Gain Therapeutics shares rise 5.20% intraday after BioXcel Therapeutics announces positive FDA Pre-sNDA. - AInvest
Can BioXcel’s New Developments Boost Their Stock? - timothysykes.com
BioXcel Shares Jump After Encouraging FDA Feedback on BXCL501 Home-Use Expansion - MSN
Bioxcel Therapeutics Soars 34.67% on FDA sNDA Alignment - AInvest
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, and Other Gainers & Losers - AInvest
BioXcel receives FDA alignment for IGALMI at-home use submission - Investing.com
BioXcel stock surges after positive FDA feedback on BXCL501 expansion - Investing.com
BioXcel Therapeutics Aligns with FDA on sNDA for IGALMI Label Expansion to At-Home Use, Submission Planned for Q1 2026 - Quiver Quantitative
BioXcel Therapeutics receives positive FDA feedback on sNDA submission. - AInvest
BioXcel Therapeutics Announces Positive FDA Pre-sNDA - GlobeNewswire
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia - MarketScreener
First-Ever At-Home Agitation Drug: BioXcel's IGALMI Moves Closer to Outpatient Bipolar/Schizophrenia Use - Stock Titan
Bioxcel Therapeutics Soars 18.8% on Phase III Trial Announcement - AInvest
Will Breakout in BioXcel Therapeutics Inc. Sustain Through Next WeekJuly 2025 Price Swings & Technical Buy Zone Confirmations - beatles.ru
BioXcel Therapeutics Inc. Testing Reversal Zone on Weekly ChartEarnings Trend Report & Comprehensive Market Scan Insights - 선데이타임즈
BioXcel Therapeutics Receives Positive FDA Feedback Ahead of Pre-sNDA Meeting - AInvest
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioxcel Therapeutics Inc Stock (BTAI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mehta Vimal | CEO and President |
Dec 16 '24 |
Sale |
0.36 |
3,117 |
1,131 |
59,605 |
| Steinhart Richard I | Chief Financial Officer |
Dec 16 '24 |
Sale |
0.36 |
577 |
207 |
20,932 |
| Rodriguez Javier | See Remarks |
Dec 16 '24 |
Sale |
0.36 |
430 |
153 |
24,423 |
| Yocca Frank | Chief Scientific Officer |
Dec 16 '24 |
Sale |
0.35 |
430 |
152 |
28,931 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):